The tumor cells with JAK1/JAK2 gene mutation were not sensitive to the killing effect of IFN, and the expression of PD‐L1 was downregulated, making the tumor cells resistant to PD‐1/PD‐L1 monoclonal antibody.138, 139. The gene discussed is JAK1; the disease is neoplasm.